PURPOSE: Recent genome-wide screens have identified genetic variations in ARID5B associated with susceptibility to childhood acute lymphoblastic leukemia (ALL). We sought to determine the contribution of ARID5B single nucleotide polymorphisms (SNPs) to racial disparities in ALL susceptibility and treatment outcome. PATIENTS AND METHODS: We compared the association between ARID5B SNP genotype and ALL susceptibility in whites (> 95% European genetic ancestry; 978 cases and 1,046 controls) versus in Hispanics (> 10% Native American ancestry; 330 cases and 541 controls). We determined the relationships between ARID5B SNP genotype and ALL relapse risk in 1,605 children treated on the Children's Oncology Group (COG) P9904/9905 clinical trials. RESULTS: Among 49 ARID5B SNPs interrogated, 10 were significantly associated with ALL susceptibility in both whites and Hispanics (P < .05), with risk alleles consistently more frequent in Hispanics than in whites. rs10821936 exhibited the most significant association in both races (P = 8.4 × 10(-20) in whites; P = 1 × 10(-6) in Hispanics), and genotype at this SNP was highly correlated with local Native American genetic ancestry (P = 1.8 × 10(-8)). Multivariate analyses in Hispanics identified an additional SNP associated with ALL susceptibility independent of rs10821936. Eight ARID5B SNPs were associated with both ALL susceptibility and relapse hazard; the alleles related to higher ALL incidence were always linked to poorer treatment outcome and were more frequent in Hispanics. CONCLUSION: ARID5B polymorphisms are important determinants of childhood ALL susceptibility and treatment outcome, and they contribute to racial disparities in this disease.
PURPOSE: Recent genome-wide screens have identified genetic variations in ARID5B associated with susceptibility to childhood acute lymphoblastic leukemia (ALL). We sought to determine the contribution of ARID5B single nucleotide polymorphisms (SNPs) to racial disparities in ALL susceptibility and treatment outcome. PATIENTS AND METHODS: We compared the association between ARID5B SNP genotype and ALL susceptibility in whites (> 95% European genetic ancestry; 978 cases and 1,046 controls) versus in Hispanics (> 10% Native American ancestry; 330 cases and 541 controls). We determined the relationships between ARID5B SNP genotype and ALL relapse risk in 1,605 children treated on the Children's Oncology Group (COG) P9904/9905 clinical trials. RESULTS: Among 49 ARID5B SNPs interrogated, 10 were significantly associated with ALL susceptibility in both whites and Hispanics (P < .05), with risk alleles consistently more frequent in Hispanics than in whites. rs10821936 exhibited the most significant association in both races (P = 8.4 × 10(-20) in whites; P = 1 × 10(-6) in Hispanics), and genotype at this SNP was highly correlated with local Native American genetic ancestry (P = 1.8 × 10(-8)). Multivariate analyses in Hispanics identified an additional SNP associated with ALL susceptibility independent of rs10821936. Eight ARID5B SNPs were associated with both ALL susceptibility and relapse hazard; the alleles related to higher ALL incidence were always linked to poorer treatment outcome and were more frequent in Hispanics. CONCLUSION:ARID5B polymorphisms are important determinants of childhood ALL susceptibility and treatment outcome, and they contribute to racial disparities in this disease.
Authors: Sohee Han; Kyoung-Mu Lee; Sue K Park; Jong Eun Lee; Hyo Seop Ahn; Hee Young Shin; Hyoung Jin Kang; Hong Hoe Koo; Jong Jin Seo; Ji Eun Choi; Yoon-Ok Ahn; Daehee Kang Journal: Leuk Res Date: 2010-02-26 Impact factor: 3.156
Authors: Eric J Chow; Susan E Puumala; Beth A Mueller; Susan E Carozza; Erin E Fox; Scott Horel; Kimberly J Johnson; Colleen C McLaughlin; Peggy Reynolds; Julie Von Behren; Logan G Spector Journal: Cancer Date: 2010-06-15 Impact factor: 6.860
Authors: Jun J Yang; Cheng Cheng; Meenakshi Devidas; Xueyuan Cao; Yiping Fan; Dario Campana; Wenjian Yang; Geoff Neale; Nancy J Cox; Paul Scheet; Michael J Borowitz; Naomi J Winick; Paul L Martin; Cheryl L Willman; W Paul Bowman; Bruce M Camitta; Andrew Carroll; Gregory H Reaman; William L Carroll; Mignon Loh; Stephen P Hunger; Ching-Hon Pui; William E Evans; Mary V Relling Journal: Nat Genet Date: 2011-02-06 Impact factor: 38.330
Authors: John Jack; Tammy M Havener; Howard L McLeod; Alison A Motsinger-Reif; Matthew Foster Journal: Pharmacogenomics Date: 2015-08-28 Impact factor: 2.533
Authors: Kyle M Walsh; Adam J de Smith; Tara C Welch; Ivan Smirnov; Marc J Cunningham; Xiaomei Ma; Anand P Chokkalingam; Gary V Dahl; William Roberts; Lisa F Barcellos; Patricia A Buffler; Catherine Metayer; Joseph L Wiemels Journal: Am J Hematol Date: 2014-04-18 Impact factor: 10.047
Authors: Stephen P Hunger; Mignon L Loh; James A Whitlock; Naomi J Winick; William L Carroll; Meenakshi Devidas; Elizabeth A Raetz Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Guolian Kang; Wenjian Bi; Yanlong Zhao; Ji-Feng Zhang; Jun J Yang; Heng Xu; Mignon L Loh; Stephen P Hunger; Mary V Relling; Stanley Pounds; Cheng Cheng Journal: Hum Hered Date: 2014-07-30 Impact factor: 0.444
Authors: K M Walsh; A P Chokkalingam; L-I Hsu; C Metayer; A J de Smith; D I Jacobs; G V Dahl; M L Loh; I V Smirnov; K Bartley; X Ma; J K Wiencke; L F Barcellos; J L Wiemels; P A Buffler Journal: Leukemia Date: 2013-04-25 Impact factor: 11.528